ResearchMulticenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting
ResearchExploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive/HER2-negative breast cancer
ResearchClinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer
ResearchThe global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and control
ResearchImlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer
ResearchKEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
ResearchClinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer
ResearchDetection of actionable mutations in the cerebrospinal fluid and concordance/discordance with extracranial disease in patients with breast cancer brain metastases
ResearchSacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from clinical trials
ResearchOPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with metastatic breast cancer
ResearchReal-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- breast cancer
ResearchReal-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- breast cancer
ResearchOptimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer
ResearchCirculating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors